Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 2 Radiation Injuries 1 Prostatic Neoplasms 1 Popliteal Cyst 1 Pneumonia 1 Optic Neuritis 1 Myelitis, Transverse 1 Myelitis 1 Myasthenia Gravis 1 Glioma 1 Breast Neoplasms 1 Arthritis, Rheumatoid 1

Interventions

Prednisone 54 Radiotherapy 52 Docetaxel 51 Leuprolide 48 Goserelin 47 bicalutamide 45 enzalutamide 30 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Androgen Antagonists 27 Flutamide 24 Triptorelin Pamoate 22 apalutamide 19 Gonadotropin-Releasing Hormone 18 Abiraterone Acetate 18 abiraterone 16 Radiation 15 Zoledronic Acid 14 Magnetic Resonance Spectroscopy 13 gallium 68 PSMA-11 12 Prednisolone 11 luprolide acetate gel depot 10 darolutamide 10 cabazitaxel 9 Radiosurgery 9 Standard of Care 8 Specimen Handling 8 Radiotherapy, Intensity-Modulated 8 Radiotherapy, Conformal 8 Estramustine 8 Dexamethasone 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Adrenal Cortex Hormones × Clear all

NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡